Sagimet Biosciences Inc. Payments of Stock Issuance Costs
Sagimet Biosciences Inc. (SGMT) reported Payments of Stock Issuance Costs of $11.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-11
- Sagimet Biosciences Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $11.14M.
- Sagimet Biosciences Inc. payments of stock issuance costs for the quarter ending 2024-03-31 was $7.80M.
- Sagimet Biosciences Inc. payments of stock issuance costs for the quarter ending 2023-09-30 was $10.27M.
- Sagimet Biosciences Inc. payments of stock issuance costs for fiscal 2024 was $7.80M, a 24.07% decline from fiscal 2023.
- Sagimet Biosciences Inc. payments of stock issuance costs for fiscal 2023 was $10.27M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|
| 2026-06-30 | $11.14M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $7.80M 10-K · filed 2026-03-11 | |
| 2024-03-31 | $7.80M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $10.27M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $10.27M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |